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Abstract
BACKGROUND: To date, Hodgkin’s lymphoma (HL) patients
have achieved long-term survival of more than 80%. Unfortu-
nately, longer follow-up has shown serious adverse effects of
the treatments used. For this reason, therapeutic strategies are
becoming more tailored to the individual patient's prognosis.
Pre-treatment risk factors for early-stage and advanced-stage
HL are well known indicators of prognosis. Recently, early in-
terim 18F-FDG PET has been shown as a strong and indepen-
dent predictor of progression-free survival in HL. Our aim was
to assess response to therapy by repeating 18F-FDG-PET/CT
after four and six chemotherapy cycles.
MATERIAL AND METHODS: We evaluated 21 consecutive pa-
tients affected by (HL) and presenting for assessment over
a period of three years. All patients underwent initial staging
with 18F-FDG-PET/CT along with standard staging procedures.
The prognostic value of 18F-FDG PET-CT
in the management of Hodgkin’s
lymphoma: preliminary results
of a prospective study
We tailored an individual treatment plan dependent on pre-treat-
ment risk factors and initial 18F-FDG-PET/CT. With the aim of
the best definition of response to treatment, we repeated
18F-FDG-PET/CT after two (FDG-PET 2), four (FDG-PET 4) and
six (FDG-PET 6) chemotherapy cycles. Chemotherapy was typ-
ically given for four cycles in early disease stages and was pro-
longed to six to eight cycles in advanced disease stages, de-
pending on PET findings.
RESULTS: Our results showed a strong negative predictive val-
ue in detecting responders in early stage HL and a positive
predictive value in advanced-stage patients. Clinical stage,
extra-nodal sites and the positivity of the 18F-FDG-PET/CT per-
formed during chemotherapy were also noted as strong deter-
minants of response to treatment. Moreover, in our series the
18F-FDG-PET/CT data obtained after only two chemotherapy
cycles (FDG-PET 2) were the same of those obtained after FDG-
PET 4 and FDG-PET 6 controls.
CONCLUSION: The preliminary data of the present study con-
firm those of previous published studies about the negative pre-
dictive value of 18F-FDG-PET/CT performed after four and six
chemotherapy cycles, which contributed to the decision to stop
treatment and to avoid radiotherapy in HL patients. Nonethe-
less, our preliminary data seems to suggest that only the
18F-FDG-PET/CT performed after two cycles of chemotherapy
(FDG-PET 2) is able to provide the same prognostic informa-
tion of the FDG-PET 4 and FDG-PET 6 earlier.
Keywords: Hodgkin’s lymphoma, 18F-FDG-PET/CT,
prognostic value
Introduction
The modern combination of chemotherapy and radiotherapy
has improved the long-term survival of patients with Hodgkin's
lymphoma (HL) to more than 80% in recent decades. However,
longer follow-up of these patients has shown serious long-term
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adverse effects related to the treatment, including heart and lung
disease, and secondary malignancies. In order to reduce these
long-term side effects, therapeutic strategies are becoming more
tailored to the individual patient's prognosis. The aim of the onco-
haematologist is to achieve the highest cure rate with the least
morbidity and mortality. Well-established pre-treatment prognos-
tic factors [1] have been shown to predict survival in large cohort
studies. Another important predictor of outcome is the response
to treatment [2]. Conventional methods for monitoring response
to treatment are based on reduction in tumour size documented
clinically and with contrast enhanced CT scan (c.e. CT). Recently,
early interim 18F-FDG PET has been shown to be a strong and
independent predictor of progression-free survival in HL patients
[3–9]. In particular, a positive early interim 18F-FDG-PET was found
to be highly predictive of disease progression in patients with
advanced stage or extra-nodal disease [8].
We present here our preliminary experience with the prognos-
tic value of the 18F-FDG PET/CT in a group of 21 HL patients, with
the aim of verifying possible correlations between the pre-treat-
ment risk factors, 18F-FDG-PET performed during chemotherapy
compared with the pre-treatment baseline examination, and the
treatment outcome.
Material and methods
We homogeneously evaluated 21 consecutive patients with
newly diagnosed HL who underwent in-therapy assessment with
18F-FDG-PET/CT since January 2004. All patients underwent ini-
tial staging with 18F-FDG-PET/CT examinations (FDG-PET 1) along
with standard staging work-up procedures including contrast en-
hanced CT (c.e. CT). 18F-FDG PET/CT was repeated after two
(FDG-PET 2) and four cycles of chemotherapy (FDG-PET 4), and
after completion of six cycles of chemotherapy (FDG-PET 6). Treat-
ment protocol was decided at baseline:
1. Patients with classic HL and advanced disease (stage IIB–IV)
were treated with six courses of ABVD. Chemotherapy was
typically given for four cycles in early disease stages while it
was prolonged to six to eight cycles in advanced disease stag-
es depending on PET findings. In detail, Chemotherapy was
stopped in the presence of a completely negative FDG-PET
4; otherwise, two more courses were given until the achieve-
ment of a completely negative FDG-PET 6. In addition, the
results of the FDG-PET after 6–8 cycles of chemotherapy were
used to decide on further courses of radiotherapy in bulky
disease.
2. Patients with early stage classic HL (I–IIA) were treated with
chemo-radiotherapy in the presence of at least one of the fol-
lowing adverse prognostic factors: bulky disease, erythrocyte
sedimentation rate > 40 mm, more than three nodal basins
involved and the presence of sub-diaphragmatic disease. Ra-
diotherapy alone was limited to stage I with no adverse prog-
nostic factors.
3. Patients with nodular lymphocyte predominance were treated
as classic HL at first presentation, while four weekly courses
of monoclonal antibody anti-CD20 (rituximab) were given when
relapse was demonstrated at an early stage.
The patients were followed-up for a period of 4–28 months
(median follow-up =17 months).
Whole-body 18F-FDG PET/CT was performed by a hybrid scan-
ner (GE Discovery LS, General Electric Medical Systems, Milwau-
kee, WI, USA) with the following procedure: (a) each patient fast-
ed for at least six hours and was intravenously injected with
5.5 MBq /Kg 18F-FDG; (b) the time elapsed between injection and
scanning was 60-90 min; (c) each patient was scanned from the
base of the skull to the mid-thigh, with an acquisition time of four
minutes per bed position with attenuation correction performed
using CT (120 keV) X-rays. The energy of the annihilation quanta
was 0.51 MeV.
For the purposes of the present study, 18F-FDG PET/CT exa-
minations were interpreted visually by two skilled nuclear medi-
cine physicians (D.R., L.R.) blinded of clinical patient data; in ca-
ses of discrepancy, final diagnosis was reached by consensus.
Results
Fifteen patients (71.4%) demonstrated negative FDG-PET 2
and FDG-PET 4 controls after the first-line chemotherapy. Of those,
14/15 patients (93.3%) had a negative FDG-PET 6 control and are
currently in complete disease remission. Only one patient (patient
2, Table 1), who was FDG-PET 2 and FDG-PET 4 negative, expe-
rienced early relapse and successive refractory responses to sal-
vage high-dose chemotherapy.
Six patients (28.6%) were FDG-PET 2 and FDG-PET 4 posi-
tive. In these patients, persistent disease was proven by tradition-
al methods, and they were treated by second-line chemotherapy.
Furthermore, three of them with evidence of persistent bulky dis-
ease at 18F-FDG PET/CT underwent successful radiotherapy. Fi-
nally, one no-responder patient was successfully treated by bone
marrow transplantation. A new post-treatment 18F-FDG PET/CT
control was negative in all these six patients and they remained in
disease-remission during subsequent follow-up.
It is worth noting that all patients affected by nodular lympho-
cyte predominance histotype had negative FDG-PET 2 and FDG-
PET 4 controls, while the three patients affected by stage III and IV
B all presented with International Prognostic Score (IPS) ≥ 3, with
two of them showing a positive FDG-PET 2 and FDG-PET 4 control.
It has to be pointed out that in this prospective study we per-
formed serial PET controls every two chemotherapy cycles. How-
ever, it is likely that in early stage responder patients, a PET scan
obtained after two cycles of chemotherapy is sufficient for obtain-
ing prognostic indications. On the other hand, we found perform-
ing a PET scan control after six or eight cycles of chemotherapy
very useful in advanced-stage disease patients to decide when to
stop treatment.
Discussion
Modern treatment regimens for early-stage HL show very high
cure and survival rates. As cure rates have improved over the
years, late adverse effects of treatment have become a matter of
increasing concern. In both early and advanced HL, further risk-
adapted therapy is being introduced to achieve high cure rates
with minimal long-term morbidity and mortality. In the case of
advanced-stage HL, where the prognosis is less favourable,
efforts have also concentrated on intensifying chemotherapy to
improve the chances of cure [10]. Primary refractory disease and
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early relapse have the worst prognosis with conventional che-
motherapy. Salvage high-dose chemotherapy with haematopoi-
etic stem cell transplantation improves the outcome of both
groups [11]. Risk-adapted therapy depends on reliable prog-
nostic stratification as early as possible during treatment. While
the prognosis can be estimated using well-established and val-
idated pre-treatment prognostic indices [1], response to treat-
ment is the most important single prognostic factor for the indi-
vidual patient [8]. Early interim 18F-FDG PET has recently been
found to be a major indicator of response to treatment in retro-
spective and prospective studies [8, 12–15]. In particular, early
interim 18F-FDG PET was stronger than all pre-treatment prog-
nostic factors when evaluated independently in univariate regres-
sion analyses, with clinical stage and extra-nodal disease also
showing considerable prognostic strength. In multivariate regres-
sion analyses, an early 18F-FDG PET control was shown to be an
independent stronger predictor of progression-free survival (PFS)
than clinical-stage and extra-nodal disease [8]. Moreover, the
negative predictive value in detecting responders of early inter-
im 18F-FDG PET has been reported to be high in early stage
patients, while the positive predictive value in predicting patients
with persistent disease is high in advanced-stage patients [8,
12]. Early 18F-FDG PET control during chemotherapy may help
risk-adapted treatment strategies by selecting good-prognosis
HL patients for less intensive and less morbid treatment, while
worse-prognosis patients destined to have short term progres-
sion or relapse may be designated for early treatment intensifi-
cation [8, 10, 13–15].
In spite of the relatively small number of cases described in
the present study, some conclusions can be made. Firstly, our
data have shown a strong negative predictive value in detecting
responders of FDG-PET 2 in our early-stage patients. One limita-
tion of our study is the relatively short post-treatment follow-up
period, especially for patients at high risk of disease relapse. On
the other hand, it should be emphasised that a very early 18F-FDG
PET/CT control, obtained after only two courses of chemotherapy
(FDG-PET 2), was effective in our early-stage HL patients with
a very high negative predictive value. However, in our responder
patient group, the FDG-PET 4 control did not add further prog-
nostic information to the FDG-PET 2 control. This information may
be useful for the early identification of responders and in planning
the most accurate course of treatment.
Some authors have suggested a semi-quantitative interpreta-
tion of the FDG-PET exam by measuring the Standardised Up-
take Value (SUV) that was found to offer some advantage over
a visual exam interpretation [13]. These data were not confirmed
in other studies [12].
It can be concluded that in common practice the 18F-FDG PET/
/CT exam has become very important in establishing a tailored
plan of treatment for HL patients. The FDG-PET 2 control is very
useful, especially in identifying responder patients, and the FDG-
-PET 4 control does not appear to add further useful information
to this purpose. The persistence of bulky disease at the FDG-PET 2
control leads to the treatment of the patient also with radiothera-
py. In contrast, in the case of negative FDG-PET 2, the adjunct of
radiotherapy seems useless. Lastly, negativity of the FDG-PET 6
represents an important step to decide subsequent follow-up.
These preliminary results need to be confirmed in larger patient
series with prolonged follow-up.
Conclusions
Our preliminary data seems to support the impression that
the performance of serial PET scans can help in modulating the
Table 1. Clinical characteristics and 18F-FDG PET/CT results in our patient series
No. Patients Histological type Clinical stage IPS* Bulky Extra–nodal FDG-PET 2**
(sex, age) disease
1. FR, F, 18 y Nod. sclerosis IVB 3 + + (lung, liver) +
2. BR, F, 35 y Nod. sclerosis IVB 3 – + (lung, liver) –
3. MG, M, 56 y Nod. sclerosis IIIB 4 + – +
4. BN, F, 30 y Nod. sclerosis IIB 0 – – –
5. BE, F, 28 y Nod. sclerosis IIB 2 + – +
6. SS, M, 27 y Nod. sclerosis IIB 2 – – +
7. AF, F, 29 y Nod. sclerosis IIB 2 + – –
8. EB, M, 55 y Nod. sclerosis IIB 3 + – –
9. VE, F, 28 y Nod. sclerosis IIB 0 + – –
10. PC, M, 45 y Nod. sclerosis IIA (unfavourable) 2 – – +
11. RG, F, 48 y Nod. sclerosis IIA (favourable) 2 – – +
12. NB, M, 48 y Mixed cellularity IIA (favourable) 2 – – –
13. DG, M, 40 y Nod. lymph. predominance IIA (relapse, favourable) 2 – – –
14. RC, M, 25 y Nod. lymph. predominance IIA (relapse, favourable) 2 – – –
15. CD, M, 25 y Nod. lymph. predominance IIA (favourable) 2 – – –
16. AM, F, 23 y Nod. lymph. predominance IIA (favourable) 1 – – –
17. GT, M, 32 y Nod. lymph. predominance IIIB 2 + – –
18. LT, M, 33 y Nod. lymph. predominance IIA (favourable) 2 – – –
19. FR, F, 20 y Nod. lymph. predominance IIA (favourable) 1 – – –
20. CM, F, 28 y Nod. lymph. predominance IIA (favourable) 1 – – –
21. GZ, F, 34 y Nod. lymph. predominance IIA (favourable) 1 – – –
*IPS — International Prognostic Score; **FDG-PET 2 — 18F-FDG PET/CT results after two cycles of chemotherapy
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treatment of Hodgkin's lymphoma patients through personalisa-
tion of the therapeutic schedule, thus avoiding aggressive ap-
proaches in early-stage responders.
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